- ►aacrjournals.org [PDF] T Kubota, K Koshizuka, EA Williamson, H Asou, … - Cancer Research, 1998 - AACR Troglitazone, a thiazolidinedione derivative, is a widely used anti- diabetic
drug that binds and activates peroxisome proliferator-activated receptor y
(PPARy) and enhances insulin sensitivity. It induces differen tiation of ... Cited by 488 - Related articles - BL Direct - All 4 versions
- ►jcojournal.org EJ Small, P Fratesi, DM Reese, G Strang, R … - Journal of Clinical Oncology, 2000 - jcojournal.org PURPOSE: Provenge (Dendreon Corp, Seattle, WA) is an immunotherapy product
consisting of autologous dendritic cells loaded ex vivo with a recombinant
fusion protein consisting of prostatic acid phosphatase (PAP) linked to ... Cited by 348 - Related articles - BL Direct - All 6 versions
HP Koeffler - Clinical Cancer Research, 2003 - AACR The peroxisome proliferator-activated receptor γ (PPARγ) ligands have
anticancer activity against a wide variety of neoplastic cells in vitro. Animal
studies have chronicled their in vivo anticancer effects and ... Cited by 209 - Related articles - BL Direct - All 8 versions
- ►annals.org CM Coley, MJ Barry, C Fleming, AG Mulley - Annals of Internal Medicine, 1997 - Am Coll Physicians Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
Purpose: To estimate the prevalence of clinically important prostate cancer ... Cited by 185 - Related articles - BL Direct - All 7 versions
- ►annals.org [PDF] CM Coley, MJ Barry, C Fleming, MC Fahs, AG … - Annals of internal medicine, 1997 - Am Coll Physicians I n this paper, we synthesize the evidence on the epidemiology of prostate
cancer and the effec- tiveness of screening tests that were presented in part I
of this paper (1). We also examine evidence of treatment effectiveness to ... Cited by 152 - Related articles - BL Direct - All 7 versions
- ►ascopubs.org EJ Small, M Meyer, ME Marshall, LM Reyno, … - Journal of Clinical Oncology, 2000 - jco.ascopubs.org PATIENTS AND METHODS: A double-blind, placebo-controlled trial randomized
patients to receive a 78-day, outpatient regimen of either suramin plus
hydrocortisone (HC, 40 mg/d) or placebo plus HC. Treatment assignment was ... Cited by 143 - Related articles - BL Direct - All 8 versions
- ►endojournals.org SA Stoch, RA Parker, L Chen, G Bubley, YJ Ko … - Journal of Clinical Endocrinology & Metabolism, 2001 - Endocrine Soc Prostate cancer is the most common visceral malignancy in men. As the tumor is
testosterone dependent, a frequent treatment modality involves therapy with GnRH
agonists (GnRH-a) resulting in hypogonadism. Because testosterone is ... Cited by 136 - Related articles - BL Direct - All 7 versions
X Gao, DJ Grignon, T Chbihi, A Zacharek, YQ … - Urology, 1995 - Elsevier Prostate cancer is the most frequently diagnosed cancer and the second leading
cause of cancer death in males in the United States. The mortality is due mainly
to distant metastasis. Therefore, predicting the prognosis of prostate ... Cited by 120 - Related articles - BL Direct - All 7 versions
E David Crawford, CL Bennett, NN Stone - Urology, 1997 - Elsevier Prostate cancer will account for 334,500 new cases and 41,800 deaths among men
in the United States in 1997. Patients and physicians are faced with many
concerns related to benefits and side effects of alternative treatments, ... Cited by 104 - Related articles - BL Direct - All 4 versions
RM Merrill, OW Brawley - Epidemiology, 1997 - jstor.org Prostate cancer is currently the most frequently diag- nosed cancer and the
second leading cause of cancer death among men in the United States.1 Blacks
have higher incidence and mortality rates than do whites, with the trend in ... Cited by 95 - Related articles - BL Direct - All 5 versions
